Current Rheumatology Reports

, 15:378 | Cite as

Updated Review of Complementary and Alternative Medicine Treatments for Systemic Lupus Erythematosus

  • Carol M. GrecoEmail author
  • Claire Nakajima
  • Susan Manzi
Part of the following topical collections:
  1. Topical Collection on Complementary and Alternative Medicine


It is estimated that over 50 % of patients with systemic lupus erythematosus (SLE) have utilized complementary and alternative medicine (CAM) treatments to reduce symptoms and manage their health. However, there are relatively few randomized controlled trials of CAM for SLE. This review describes recent studies of vitamins and supplements, acupuncture, and mind-body interventions in SLE patients. The recent trials of CAM treatments for SLE indicate that supplements such as vitamin D, omega 3 fatty acids, N-acetyl cysteine and turmeric show some promise for reducing SLE disease activity. In addition, mind-body methods such as cognitive-behavioral therapy and other counseling interventions may improve mood and quality of life in SLE.


Systemic lupus erythematosus Complementary medicine Alternative medicine Integrative medicine Supplements Acupuncture Vitamins Mind–body treatments Cognitive behavioral therapy Meditation Interpersonal therapy N-acetyl cysteine Turmeric DHEA Vitamin D Vitamin C Vitamin E Vitamin B6 Omega 3 fatty acids Fish oil Oxidative stress Anti-oxidants 



Carol M. Greco and Susan Manzi have received grant support from the National Institutes of Health (NIH) (R01 AR046588 and K24 AR002213 for Susan Manzi). Susan Manzi has also served on an NIAID-NIH study section. Carol M. Greco also receives support from the NIH-National Institute of Arthritis, Musculoskeletal and Skin Diseases (R01 AR057338) and National Center for Complementary and Alternative Medicine (R01 AT006453).

The authors would like to acknowledge and thank Dr. Mary Lou Klem, research librarian at the University of Pittsburgh’s Health Sciences Library System, for conducting literature searches for this article.

Compliance with Ethics Guidelines

Conflict of Interest

Susan Manzi serves on the board for the Lupus Foundation of America, serves as a consultant for Exagen Diagnostics, and has been the co-holder of several patents.

Carol M. Greco and Claire Nakajima declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors. With regard to the authors’ research cited in this paper, all procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Manzi S, Meilahn E, Rairie J, Conte C, Medsger T, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Ward M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42(2):338–46.PubMedCrossRefGoogle Scholar
  3. 3.
    Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61(6):822–9.PubMedCrossRefGoogle Scholar
  4. 4.
    • Haija AJ, Schulz SW. The role and effect of complementary and alternative medicine in systemic lupus erythematosus. Rheum Dis Clin North Am. 2011;37(1):47–62. This paper provides a review and discussion of CAM in SLE and other rheumatologic conditions. PubMedCrossRefGoogle Scholar
  5. 5.
    Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008;(12):1–23.Google Scholar
  6. 6.
    Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT. Why US adults use dietary supplements. JAMA Intern Med. 2013;173(5):355–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum. 2000;43(6):1410–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Leong KP, Chan SP. Why Lupus patients use alternative medicine. Lupus. 2003;12:659–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Alvarez-Nemegyei J, Bautista-Botello A. Complementary or alternative therapy use and health status in systemic lupus erythematosus. Lupus. 2009;18:159–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Aghdassi E, Morrison S, Landolt-Marticorena C, Su J, Pineau CA, Gladman D, et al. The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosus. J Rheumatol. 2010;37(1):87–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Costenbader KH, Kang JH, Karlson EW. Antioxidant intake and risks of rheumatoid arthritis and systemic lupus erythematosus in women. Am J Epidemiol. 2010;172(2):205–16.PubMedCrossRefGoogle Scholar
  12. 12.
    Hiraki LT, Munger KL, Costenbader KH, Karlson EW. Dietary intake of vitamin D during adolescence and risk of adult-onset systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res. 2012;64(12):1829–36.CrossRefGoogle Scholar
  13. 13.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Kamen DL, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep. 2008;10(4):273–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Kamen DL. Vitamin D in lupus - new kid on the block? Bull NYU Hosp Jt Dis. 2010;68(3):218–22.PubMedGoogle Scholar
  16. 16.
    Szodoray P, Tarr T, Bazso A, Poor G, Szegedi G, Kiss E. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scand J Rheumatol. 2011;40(2):122–6.PubMedGoogle Scholar
  17. 17.
    Ravenell RL, Kamen DL, Spence JD, Hollis BW, Fleury TJ, Janech MG, et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci. 2012;344(4):268–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Yeap SS, Othman AZ, Zain AA, Chan SP. Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int J Rheum Dis. 2012;15(1):17–24.PubMedCrossRefGoogle Scholar
  19. 19.
    • Abou-Raya A, Abou-Raya S, Helmii M. The Effect of Vitamin D Supplementation on Inflammatory and Hemostatic Markers and Disease Activity in Patients with Systemic Lupus Erythematosus: A Randomized Placebo-controlled Trial. J Rheumatol. 2013;40(3):265–72. This paper describes a RCT of Vitamin D in 178 SLE patients. Twelve months of supplementation was associated with reduction in SLEDAI as well as modulation of proinflammatory and hemostatic markers. PubMedCrossRefGoogle Scholar
  20. 20.
    Aranow C, Dall'Era M, Massarotti EM, Mackay M, Coca A, Koumpouras F, et al. A double-blind randomized placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(10 (supplement)):S1110.Google Scholar
  21. 21.
    Minami Y, Sasaki T, Arai Y, Kurisu Y, Hisamichi S. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol. 2003;30(4):747–54.PubMedGoogle Scholar
  22. 22.
    Minami Y, Hirabayashi Y, Nagata C, Ishii T, Harigae H, Sasaki T, et al. Intakes of vitamin B6 and dietary fiber and clinical course of systemic lupus erythematosus: a prospective study of Japanese female patients. J Epidemiol. 2011;21(4):246–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Tam LS, Li EK, Leung VY, Griffith JF, Benzie IF, Lim PL, et al. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol. 2005;32(2):275–82.PubMedGoogle Scholar
  24. 24.
    Ward M. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. Am J Kidney Dis. 2000;36(3):516–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112(4):298–304.PubMedCrossRefGoogle Scholar
  26. 26.
    James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(1 Suppl):343S–8S.PubMedGoogle Scholar
  27. 27.
    Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol. 2004;31(8):1551–6.PubMedGoogle Scholar
  28. 28.
    Wright SA, O'Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008;67(6):841–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 1989;36(4):653–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Clark WF, Parbtani A, Naylor CD, Levinton CM, Muirhead N, Spanner E, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int. 1993;44(1):75–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Walton AJ, Snaith ML, Locniskar M, Cumberland AG, Morrow WJ, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis. 1991;50(7):463–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Gergely Jr P, Grossman C, Niland B, Puskas F, Neupane H, Allam F, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46(1):175–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Shah D, Aggarwal A, Bhatnagar A, Kiran R, Wanchu A. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic Res. 2011;45(5):559–67.PubMedCrossRefGoogle Scholar
  34. 34.
    Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Panomvana Na Ayudhya D. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J Clin Pharm Ther. 2010;35(4):483–5.PubMedGoogle Scholar
  35. 35.
    Tewthanom K, Janwitayanujit S, Totemchockchyakarn K, Panomvana Na Ayudhya D. Pharmacodynamic effect of N-Acetylcysteins as adjunctive therapy in mild systemic lupus erythematosus patients. Trop J Pharm Res. 2011;10(2):141–6.CrossRefGoogle Scholar
  36. 36.
    • Lai Z-W, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64(9):2937–46. This study evaluated 3 doses of NAC and placebo in 36 SLE patients. Positive effects were found on SLEDAI scores, anti-dsDNA, and BILAG.PubMedCrossRefGoogle Scholar
  37. 37.
    • Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(5):1313–8. In 24 SLE patients from the Lai et al. (2012) study, above, NAC was associated with self-reported improvements in cognitive function. PubMedCrossRefGoogle Scholar
  38. 38.
    Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol. 2007;595:425–51.PubMedCrossRefGoogle Scholar
  40. 40.
    Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012;22(1):50–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(11):2924–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Chang DM, Chu SJ, Chen HC, Kuo SY, Lai JH. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Ann Rheum Dis. 2004;63(12):1623–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46(7):1820–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50(9):2858–68.PubMedCrossRefGoogle Scholar
  45. 45.
    van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8(3):181–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, et al. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008;35(8):1567–75.PubMedGoogle Scholar
  47. 47.
    Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH, et al. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis. 2010;69(6):1144–7.PubMedCrossRefGoogle Scholar
  48. 48.
    van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol. 1998;25(2):285–9.PubMedGoogle Scholar
  49. 49.
    Marder W, Somers EC, Kaplan MJ, Anderson MR, Lewis EE, McCune WJ. Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study. Lupus. 2010;19(10):1229–36.PubMedCrossRefGoogle Scholar
  50. 50.
    Vickers AJ, Cronin AM, Maschino AC, Lewith G, MacPherson H, Foster NE, et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med. 2012;172(19):1444–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Greco CM, Kao AH, Maksimowicz-McKinnon K, Glick RM, Houze M, Sereika SM, et al. Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study. Lupus. 2008;17(12):1108–16.PubMedCrossRefGoogle Scholar
  52. 52.
    Scharf H, Mansmann U, Streitberger K, Witte S, Kramer J, Maier C, et al. Acupuncture and knee osteoarthritis. Ann Intern Med. 2006;145:12–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Josefson A, Kreuter M. Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases. Rheumatology (Oxford). 2003;42:1149–54.CrossRefGoogle Scholar
  54. 54.
    Sundquist K, Li X, Hemminki K, Sundquist J. Subsequent risk of hospitalization for heuropsyciatric disorders in patients with rheumatic diseases: a nationwide study from Sweden. Arch Gen Psychiatry. 2008;65(5):501–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Daleboudt GM, Broadbent E, McQueen F, Kaptein AA. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res. 2011;63(3):342–50.Google Scholar
  56. 56.
    Greco CM, Li T, Sattar A, Kao AH, Danchenko N, Edmundowicz D, et al. Association between depression and vascular disease in systemic lupus erythematosus. J Rheumatol. 2012;39(2):262–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Zhang J, Wei W, Wang C. Effects of psychological interventions for patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus. 2012;21(10):1077–87.PubMedCrossRefGoogle Scholar
  58. 58.
    Karlson EW, Liang MH, Eaton H, Huang J, Fitzgerald L, Rogers MP, et al. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50(6):1832–41.PubMedCrossRefGoogle Scholar
  59. 59.
    Harrison MJ, Morris KA, Horton R, Toglia J, Barsky J, Chait S, et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology. 2005;65(8):1325–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Drenkard C, Dunlop-Thomas C, Easley K, Bao G, Brady T, Lim SS. Benefits of a self-management program in low-income African-American women with systemic lupus erythematosus: results of a pilot test. Lupus. 2012;21(14):1586–93.PubMedCrossRefGoogle Scholar
  61. 61.
    Navarrete-Navarrete N, Peralta-Ramirez MI, Sabio-Sanchez JM, Coin MA, Robles-Ortega H, Hidalgo-Tenorio C, et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom. 2010;79(2):107–15.PubMedCrossRefGoogle Scholar
  62. 62.
    Greco CM, Rudy TE, Manzi S. Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum. 2004;51(4):625–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Brown RT, Shaftman SR, Tilley BC, Anthony KK, Kral MC, Maxson B, et al. The health education for lupus study: a randomized controlled cognitive-behavioral intervention targeting psychosocial adjustment and quality of life in adolescent females with systemic lupus erythematosus. Am J Med Sci. 2012;344(4):274–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Morone NE, Greco CM, Weiner DK. Mindfulness meditation for the treatment of chronic low back pain in older adults: a randomized controlled pilot study. Pain. 2008;134(3):310–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Kabat-Zinn J, Wheeler EP, Light T, Skillings A, Scharf MJ, Cropley TG, et al. Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients With Moderate to Severe Psoriasis Undergoing Photo Therapy (UVB) and Photochemotherapy (PUVA). Psychosom Med. 1998;60(5):625–32.PubMedGoogle Scholar
  66. 66.
    Rosenkranz MA, Davidson RJ, Maccoon DG, Sheridan JF, Kalin NH, Lutz A. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain Behav Immun. 2013;27(1):174–84.PubMedCrossRefGoogle Scholar
  67. 67.
    Pradhan EK, Baumgarten M, Langenberg P, Handwerger B, Gilpin AK, Magyari T, et al. Effect of Mindfulness-Based Stress Reduction in rheumatoid arthritis patients. Arthritis Rheum. 2007;57(7):1134–42.PubMedCrossRefGoogle Scholar
  68. 68.
    Rosenzweig S, Greeson JM, Reibel DK, Green JS, Jasser SA, Beasley D. Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice. J Psychosom Res. 2010;68(1):29–36.PubMedCrossRefGoogle Scholar
  69. 69.
    Zautra AJ, Davis MC, Reich JW, Nicassario P, Tennen H, Finan P, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol. 2008;76(3):408–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.UPMC Shadyside Center for Integrative MedicineUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Teachers CollegeColumbia UniversityNew YorkUSA
  3. 3.Allegheny Health Network Department of MedicineTemple University School of MedicinePittsburghUSA

Personalised recommendations